Matching slides 303,780
Current window 203,011-203,040
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all

Component

203,011-203,040 of 303,780

filter-aware
23
The slide uses a scatter plot format with a shared legend for patient IDs and dose levels.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations 1 hit
25
Patients with baseline levels of SMRP in normal range were excluded. Data cutoff: September 9, 2022.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations 1 hit
27
The chart displays individual patient responses, with multiple patients achieving significant tumor regression.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations 1 hit
28
The slide uses a numbered list format to categorize clinical trial improvements.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations 1 hit
29
Includes a futility analysis note for MPM arms and collaboration branding.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations 1 hit
30
The chart shows the breakdown of patient eligibility by MSLN expression levels (50%, 2+/3+ vs 50%, 1+ vs Not eligible).TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations 1 hit
31
The chart is a swimmer plot showing patient response over time, including redosing events and disease progression.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations 1 hit
33
The chart uses horizontal bars to represent the development stage of each program.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations 1 hit
34
The slide features a large stylized '2' from the company logo as a background element.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations 1 hit
01
Slide 1
Third Harmonic Bio | IPO Presentation Deck | 24 slidesThird Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank 1 hit
02
Third Harmonic Bio | IPO Presentation Deck | 24 slidesThird Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank 1 hit
03
Third Harmonic Bio | IPO Presentation Deck | 24 slidesThird Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank 1 hit
04
Third Harmonic Bio | IPO Presentation Deck | 24 slidesThird Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank 1 hit
07
The slide presents a summary of preclinical efficacy and safety data alongside a table demonstrating high selectivity against other kinases.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Beat · SolutionLoop · Cost Of Inaction1 hit
09
The chart displays multiple dose cohorts (200mg QD, 200mg BID, 400mg BID, 500mg QD FED) with error bars representing standard deviation.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
10
The table displays counts and percentages of subjects experiencing specific adverse events. 'MAD' stands for Multiple Ascending Dose.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
11
The chart tracks neutrophil levels across multiple cohorts (placebo, 200mg QD, 200mg Q12H, 400mg Q12H, 500mg QD FED) from Day 1 to Day 70/EOS, with a vertical line marking the end of treatment at Day 14.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
13
Includes two line charts: one normalized to baseline and one showing absolute values.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
14
The schematic illustrates a dose escalation study with three cohorts of 10 patients each, separated by safety review committee (SRC) checkpoints.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
15
The chart shows a pharmacokinetic (PK) profile comparing two formulations of THB001.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
16
The slide uses clinical data to justify a new indication for a drug candidate by highlighting the role of mast cells in asthma pathophysiology.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
17
The slide outlines a randomized, placebo-controlled trial structure with specific allergen challenge points.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
19
Third Harmonic Bio | IPO Presentation Deck | 24 slidesThird Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
22
DART stands for developmental and reproductive toxicology.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Quick Win Big Bet1 hit
23
SAD = Single Ascending Dose; FE = Food Effect; PK = Pharmacokinetics; SAE = Serious Adverse Event; AE = Adverse Event; PBO = Placebo.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Quick Win Big Bet1 hit
24
MAD = Multiple Ascending Dose study. Data shows transient changes in reticulocytes and hemoglobin levels during treatment.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Quick Win Big Bet1 hit
01
Slide 1
TurnOnGreen | Investor Presentation Deck | 23 slidesTurnOnGreen | Investor Presentation Deck | 23 slides · TurnOnGreen
Pitch deck Investor relations 1 hit
02
TurnOnGreen | Investor Presentation Deck | 23 slidesTurnOnGreen | Investor Presentation Deck | 23 slides · TurnOnGreen
Pitch deck Investor relations 1 hit
03
The slide uses a timeline to show the evolution from Digital Power Corporation (1969) to the current public entity.TurnOnGreen | Investor Presentation Deck | 23 slides · TurnOnGreen
Pitch deck Investor relations 1 hit
07
Data source: Kelley Blue Book 2022.TurnOnGreen | Investor Presentation Deck | 23 slides · TurnOnGreen
Pitch deck Investor relations Beat · Market Size1 hit